Charles River Labs Announces CEO Transition: Birgit Girshick to Succeed James Foster

summarizeSummary

Charles River Laboratories announced a planned CEO transition, with COO Birgit Girshick succeeding James C. Foster, who will remain a non-executive director.

check_boxKey Events

• CEO Transition Announced

  James C. Foster will step down as Chief Executive Officer and Chairman of the Board, effective May 5, 2026.

• New CEO Appointed

  Birgit Girshick, current Chief Operating Officer, will be appointed as the new Chief Executive Officer and join the Board, effective May 5, 2026.

• Board Chair Change

  Dr. Martin Mackay, the current Lead Independent Director, is expected to become Chair of the Board, effective May 5, 2026.

• Outgoing CEO's Continued Role

  Mr. Foster is expected to remain a non-executive director of the Board following the transition.

auto_awesomeAnalysis

Charles River Laboratories International, Inc. has announced a significant leadership transition, with long-serving Chairman, President, and CEO James C. Foster stepping down from his executive roles. The planned succession involves the appointment of current Chief Operating Officer Birgit Girshick as the new CEO, effective May 5, 2026. This internal promotion signals continuity in the company's strategic direction. Mr. Foster will remain on the Board as a non-executive director, providing ongoing experience and guidance. The appointment of Dr. Martin Mackay as the new Board Chair further solidifies the governance structure. The substantial compensation package for Ms. Girshick, including a $9 million equity grant, aligns with the responsibilities of leading a large-cap company. The consent from Elliott Investment Management L.P. for the board expansion indicates activist investor alignment with the succession plan.